Skip to main content

Table 1 Description of the sample

From: Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer’s disease (DELCODE)

 

CO (n = 141)

SCD (n = 126)

MCI (n = 65)

AD (n = 40)

Relatives of AD patients (n = 22)

F value/χ2 value

Age (years), mean (SD)

68.6 (5.1)

71.4 (5.7)***

72.8 (5.2)***

72.8 (7.1)**

64.8 (4.5)**

15.4, p > 0.001

Sex (female), n (%)

83 (58.9)

65 (51.6)

25 (38.5)**

23 (57.5)

12 (54.5)

7.9, n.s.

Education (years), mean (SD)

15.0 (2,7)

14.7 (3.1)

14.1 (3.1)

13.2 (3.2)**

13.7 (2.6)*

3.78, p = 0.005

MMSE, mean (SD)

29.4 (0.9)

29.1 (1.0)

28.0 (1.6)***

23.6 (3.3)***

29.0 (1.2)

135, p < 0.001

CDR, mean (SD)

0.0 (0.0)

0.2 (0.2)***

0.5 (0.1)***

0.8 (0.2)***

0.1 (0.2)

216, p < 0.001

CDR-SOB, mean (SD)

0.0 (0.1)

0.4 (0.4)***

1.6 (1.2)***

4.7 (1.3)***

0.4 (1.0)

343, p < 0.001

ADAScog 13, mean (SD)

5.6 (3.3)

7.0 (3.9)**

15.3 (6.3)***

29.1 (8.1)***

8.0 (5.2)

220, p < 0.001

FAQ, mean (SD)

0.1 (0.4)

0.8 (1.2)***

3.5 (4.4)***

11.8 (6.2)***

0.4 (1.0)

154, p < 0.001

GDS, mean (SD)

0.7 (1.4)

1.9 (1.7)***

1.8 (1.6)***

2.1 (1.5)***

1.1 (1.3)

12.5, p < 0.001

APOE genotype

(n = 131)

(n = 114)

(n = 60)

(n = 36)

(n = 19)

 

 APOE4 genotype of all APOE, n (%)

23 (17.6)

37 (32.5)**

22 (36.7)**

25 (69.4)***

8 (42.1)*

37.3, p < 0.001

CSF biomarkers

(n = 50)

(n = 45)

(n = 35)

(n = 18)

(n = 6)

 

 Aβ42 (pg/ml), mean (SD)

890 (323)

748 (329)*

630*** (303)

353 (100)***

684 (415)

11.1, p < 0.001)

 Aβ42 < 496 pg/ml, n (%)

5 (10.0)

9 (20.0)

16 (45.7)***

18 (100)***

2 (33.3)

54.9, p < 0.001

 Aβ42/Aβ40, mean (SD)

0.099 (0.022)

0.093 (0.026)

0.077 (0.031)**

0.046 (0.015)***

0.077 (0.036)

16.0, p < 0.001

 Aβ42/Aβ40 < 0.09, n (%)

14 (28.0)

17 (37.8)

21 (60.0)**

17 (94.4)***

4 (66.7)

28.3, p < 0.001

 tTau (pg/ml), mean (SD)

359 (159)

366 (157)

502** (224)

742 (309)***

370 (108)

15.6, p < 0.001

 tTau > 470 pg/ml, n (%)

8 (16.0)

11 (24.4)

16 (45.7)**

15 (83.3)***

1 (16.7)

31.9, p < 0.001

 pTau 181 (pg/ml), mean (SD)

51 (20)

51 (24)

67 (33)*

91 (43)***

53 (16)

9.3, p < 0.001

 pTau 181 > 57 pg/ml, n (%)

15 (30.0)

14 (31.1)

20 (57.1)*

15 (83.3)***

3 (50.0)

20.9, p < 0.001

 Aβ42/Tau ratio, Hulstaert formula, mean (SD)

1.36 (0.38)

1.15 (0.47)*

0.84 (0.49)***

0.34 (0.14)***

1.03 (0.63)

22.0, p < 0.001

 Abnormal Aβ42/Tau ratio, Hulstaert formula, n (%)

7 (14.0)

16 (35.6)**

23 (65.7)***

18 (100)***

2 (33.3)

46.7, p < 0.001

  1. Post-hoc unadjusted p value in comparison to the control group: *p < 0.05, **p < 0.01, ***p < 0.001
  2. Aβ42 beta-amyloid 42, AD Alzheimer’s disease, ADAScog 13 Alzheimer’s Disease Assessment Scale—cognitive part, APOE apolipoprotein E, CDR Clinical Dementia Rating, CDR-SOB Clinical Dementia Rating—sum of boxes, CO control group, CSF cerebrospinal fluid, FAQ Functional Activities Questionnaire, GDS Geriatric Depression Scale, MCI mild cognitive impairment, MMSE Mini-Mental -State Examination, n.s. not significant, SCD subjective cognitive decline, SD standard deviation
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193